Core Viewpoint - The introduction of Novo Nordisk's long-acting growth hormone, Pasi Growth Hormone Injection, at Boao Future Hospital provides a new treatment option for children with Growth Hormone Deficiency (GHD) in China, showing promising results in height increase within three months [1] Group 1: Product Introduction - Pasi Growth Hormone Injection has been introduced as a clinically needed drug and has already benefited over 20 children aged between 4.5 to 14.5 years with GHD [1] - The drug has demonstrated a height increase of 3-4 cm within three months of treatment [1] Group 2: Technology and Mechanism - The drug utilizes a mature technology known as fatty acid derivatization, which has been in use internationally for 36 years [1] - This technology involves single amino acid substitution in the GH molecule and reversible binding with endogenous albumin via fatty acid side chains, enhancing drug bioactivity and distribution [1] - The method allows for a prolonged half-life and sustained action, enabling administration only once a week [1] Group 3: Safety and Efficacy - The safety profile of Pasi Growth Hormone is supported by 7 years of clinical trials and real-world observations, indicating good safety characteristics [1] - The molecular structure of Pasi Growth Hormone is similar to that of human growth hormone, with metabolism primarily relying on the body's own albumin [1]

Core Viewpoint - The introduction of the long-acting growth hormone, Pasi Growth Hormone Injection, in Hainan Boao Lecheng International Medical Tourism Pilot Zone provides a new treatment option for children with growth hormone deficiency (GHD), despite the availability of domestic alternatives. This is attributed to its advanced technology, clinical efficacy, and international safety standards [1][8]. Group 1: Technology and Efficacy - The Pasi Growth Hormone Injection utilizes a mature fatty acid derivatization technology, differing significantly from the domestic product that employs PEG technology. This allows for a longer half-life and reduced dosing frequency, requiring only weekly administration instead of daily [3][6]. - Clinical data indicates that children treated with Pasi Growth Hormone can achieve an annual height increase of approximately 11.0 cm, with reported height growth of 3-4 cm within three months of treatment in the Boao Lecheng area [6][8]. Group 2: Safety and Metabolism - The drug demonstrates a high metabolic recovery rate, with over 94% of the administered dose being excreted through urine and feces by day 28, surpassing the European Medicines Agency's standard of 90% [5]. - Safety profiles show that the adverse reactions reported are common childhood illnesses, with no new safety concerns arising from the use of Pasi Growth Hormone, indicating a safety level comparable to traditional short-acting growth hormones [6][8]. Group 3: Market Implications - The introduction of Pasi Growth Hormone in the Boao Lecheng area highlights China's commitment to synchronizing international medical resources and providing better treatment options for domestic patients, thereby enhancing the overall healthcare landscape [1][8].